Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
655
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

719
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
719

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

Bone marrow transplantation·2026
Same author

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Cancer research communications·2026
Same author

External Validation, Recalibration, and Extension of a Prediction Model of Early Acute Kidney Injury in Critically Ill Children Using Multicenter Data.

Critical care explorations·2026
Same author

Impaired Cerebral Autoregulation in Pediatric Patients with ECMO: A Retrospective Analysis of ECMO Time Periods and Association with Neurologic Injury.

Neurocritical care·2026
Same author

EHR Sampling Interval Bias Detection and Burden of Blood Pressure Excursions: Implications for Clinical Decision Support and Model Validity in Pediatric ECMO.

Information (Basel)·2026
Same author

Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial.

JAMA network open·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026
Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same journal

The letter to editor regarding "real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC)".

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

New-generation platinum agents for solid tumors.

Neel Shah1, Don S Dizon

  • 1The Warren Alpert Medical School of Brown University, Providence, RI 02912, USA. neel@brown.edu

Future Oncology (London, England)
|February 27, 2009
PubMed
Summary
This summary is machine-generated.

Cisplatin revolutionized cancer treatment, but its limitations spurred the development of new platinum-based chemotherapy drugs. Despite challenges, newer agents like satraplatin and picoplatin show promise for improved cancer therapies.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.5K

Related Experiment Videos

Last Updated: Feb 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Cisplatin, a foundational chemotherapeutic agent, demonstrated significant efficacy against solid tumors and remains a cornerstone of cancer treatment.
  • Key limitations of cisplatin, including toxicity, tumor resistance, and poor oral bioavailability, have driven extensive research into developing superior platinum-based drugs.
  • Despite decades of research and numerous clinical trials, only carboplatin and oxaliplatin have achieved US FDA approval alongside cisplatin.

Purpose of the Study:

  • To review the clinical development trajectory of platinum-based anticancer agents.
  • To analyze the successes and failures in the design and approval of new platinum drugs.
  • To speculate on the future role and potential of platinum agents in cancer therapy.

Main Methods:

  • Review of historical clinical trial data for platinum-based chemotherapy agents.
  • Analysis of factors influencing the success and failure of drug development programs.
  • Examination of current Phase III trials for emerging platinum agents.

Main Results:

  • Limited success in developing new platinum agents post-cisplatin, with only carboplatin and oxaliplatin gaining FDA approval.
  • Significant investment in drug development during the 1990s yielded few breakthroughs, temporarily stalling further research.
  • Current promising agents, satraplatin and picoplatin, are in Phase III trials for prostate and lung cancers, respectively.

Conclusions:

  • The clinical development of platinum agents has been challenging, marked by high attrition rates despite initial promise.
  • The potential success of satraplatin and picoplatin could reinvigorate efforts to develop novel platinum-based cancer therapies.
  • Future research may focus on agents designed to overcome cisplatin's limitations, potentially expanding the utility of platinum drugs.